Probiodrug announced that it has received a $15m grant from the National Institutes of Health ("NIH") to partially fund the Phase IIb trial for PQ912, a small molecule glutaminyl cyclase ("QC") inhibitor in development for Alzheimer’s disease (“AD”). In addition to providing much needed cash, it provides a strong endorsement for the development of PQ912 in early AD, particularly taking into account that obtaining an NIH grant is a highly competitive process. Preparations for the US Phase IIb tri ....
20 Mar 2019
$15m cash injection from NIH for US Phase IIb in early Alzheimer's
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
$15m cash injection from NIH for US Phase IIb in early Alzheimer's
Vivoryon Therapeutics N.V. (0R3M:LON) | 0 0 0.4% | Mkt Cap: 102.2m
- Published:
20 Mar 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
Probiodrug announced that it has received a $15m grant from the National Institutes of Health ("NIH") to partially fund the Phase IIb trial for PQ912, a small molecule glutaminyl cyclase ("QC") inhibitor in development for Alzheimer’s disease (“AD”). In addition to providing much needed cash, it provides a strong endorsement for the development of PQ912 in early AD, particularly taking into account that obtaining an NIH grant is a highly competitive process. Preparations for the US Phase IIb tri ....